



ISSN Print: 2394-7500
ISSN Online: 2394-5869
Impact Factor: 5.2
IJAR 2018; 4(6): 137-141
www.allresearchjournal.com
Received: 25-04-2018
Accepted: 28-05-2018

Sunil Kumar Patra

Department of Neurosurgery,
IMS and SUM Hospital, Siksha
O Anusandhan University, K8,
Kalinga Nagar, Bhubaneswar,
Odisha, India

Souvagrya Panigrahi

Department of Neurosurgery,
IMS and SUM Hospital, Siksha
O Anusandhan University, K8,
Kalinga Nagar, Bhubaneswar,
Odisha, India

Correspondence

Souvagrya Panigrahi

Department of Neurosurgery,
IMS and SUM Hospital, Siksha
O Anusandhan University, K8,
Kalinga Nagar, Bhubaneswar,
Odisha, India

Meningitis caused by candida species: An emerging problem in neurosurgical patients: Our experience

Sunil Kumar Patra and Souvagrya Panigrahi

Abstract

Three instances of candida meningitis were experienced in a 3-year time frame in our medical clinic; all happened in neurosurgical patients. We portray these three cases and survey the 15 instances of neurosurgery-related candida meningitis recently. Information with respect to these 18 patients framed the reason for our survey. Most patients with candida meningitis had as of late gotten antibacterial specialists, and it is striking that half of patients experienced predecessor bacterial meningitis. The CSF examination uncovered neutrophilic pleocytosis that was undefined from that of bacterial meningitis. The general mortality was 11%. Organization of amphotericin B joined with flucytosine gave off an impression of being the best helpful methodology for candida meningitis. The assurance depends in a general sense on CSF culture, since in the cases we assessed the yield of gram recoloring was low and the CSF disclosures were undefined from those of bacterial meningitis. Flucytosine joined with amphotericin B warrants strong idea as antifungal treatment for candida meningitis; the perfect term of antifungal treatment remains dubious, anyway we propose that this mix treatment be overseen for no under 3 weeks. Furthermore, all shunts or ventriculostomies should be cleared for perfect accommodating outcome.

Keywords: Candida, CSF, Meningitis, CNS

Introduction

The focal sensory system and disease by *Candida* spin the last three to four decades *Candida* species have turned into the fourth reason for blood contamination in emergency clinics. This is a consequence of the boundless utilization of anti-microbials and the presence of a few clinical circumstances of delayed immunosuppression, for example, hematologic malignancies and transplants. Different circumstances that incline to candidiasis are intravascular catheters, genuine consumes, untimely infants, stomach medical procedure and i.v. tranquilize use (Bodey, 1993; Edwards, 1995). As restorative research proceeds with ebb and flow patterns, it is normal that the quantity of patients who may create candidiasis will increment. At the point when the focal sensory system (CNS) is included a vital increment in dismalness and mortality is produced. Notwithstanding the human enduring it causes, CNS candidiasis could speak to an essential increment in the measures of assets that ought to be dispensed to deal with fundamentally sick patients of this sort (Diamond, 1991). At the point when the CNS is engaged with patients with fundamental candidiasis, a few clinical indications can be ignored because of the seriousness of the patient's circumstance. The decline in the dimension of cognizance is the most successive sign of CNS candidiasis. Regularly, very little consideration is given to this sign when we go over septic patients experiencing serious diseases in concentrated consideration units, patients experiencing intrusive systems or quieted on medications. Investigations of the mind of patients who kicked the bucket from foundational candidiasis have presumed that up to half had CNS intrusion by *Candida* species (Parker *et al.*, 1981; Lipton *et al.*, 1984). Be that as it may, these patients were once in a while analyzed when alive in light of the absence of clinical signs. As of late, *Candida* species have been viewed as in charge of other neurologic clinical indications other than diminishing the dimension of cognizance. We in this manner believe that it is important to survey the full and continually changing range of neurologic pathology brought about by this microorganism.

Methods

Records of all positive CSF societies at the University of Pittsburgh Medical Center amid the

time of January 1989 to January 1993 were looked into reflectively. Three instances of candida meningitis were distinguished, and all happened in patients who experienced neurological techniques inside I month of the beginning of meningitis. We additionally looked into the recently detailed instances of candida meningitis in neurosurgical patients by utilizing MEDLINE references from 1966 through 1994. Incorporated into this survey were instances of candida meningitis in which (1) the determination was affirmed by the CSF culture, (2) the patients had experienced a neurological method inside 3 months of the beginning of candida meningitis or had an inhabiting intraventricular gadget (shunt or ventriculostomy) at the beginning of candida meningitis, and (3) satisfactory clinical information (counting basic infection, treatment, and result) were given in the report. We did exclude the cases in which candida meningitis was obtained after lumbar cut [1] or laminectomy [2].

Results

From January 1989 to January 1993, 28 instances of meningitis in neurosurgical patients were recognized at our foundation. The four most basic etiologic operators included were *Staphylococcus aureus* (21%; 6 of 28), *Staphylococcus epidermidis* (21%; 6 of 28), *Acinetobacter baumannii* (14%; 4 of 28), and *Candida* species (11%; 3 of 28). The clinical information in regards to our three patients with candida meningitis are displayed in tables I and 2. Information from these three patients in addition to the 15 patients distinguished by writing scan frame the reason for this survey. The *Candida* species included were *C. albicans* (12

cases), *C. tropicalis* (3 cases), *C. parapsilosis* (1 case), and *C. lusitaniae* (1 case); the *Candida* species was not distinguished in one case. Basic sicknesses and inclining factors. Three patients gained meningitis while at home [3-5]; all had ventriculoperitoneal shunts, which had been set up for a middle of 2 years (go, 9 months to II years) before candida meningitis happened. The rest of the 15 patients had nosocomial meningitis, as characterized by beginning following 72 hours of hospitalization. Thirteen patients had experienced a neurosurgical methodology inside 3 months of the beginning of candida meningitis: nine had a craniotomy played out a middle of 20 days (go, 4 to 30 days) before the beginning of candida meningitis, and four had a ventriculoperitoneal shunt embedded or supplanted inside 3 months (go, 10 days to 2 months) of beginning (table 3). Ten patients had intraventricular gadgets set up at the beginning of candida meningitis: 8 had ventriculoperitoneal shunts and 2 had ventriculostomies. The ventriculoperitoneal shunts had been set up for a middle of 20 days (run, 14 days to 11 years), and the ventriculostomies had been set up for 13 and 36 days, separately, before candida meningitis happened. What's more, two patients had lumbar channels embedded for, multi week before beginning of candida meningitis. Fundamental antibacterial operators and corticosteroids had been regulated to 13 patients and 5 patients, separately, inside about a month preceding the finding of candida meningitis (table 3); half (9 of 18) had included bacterial meningitis inside 3 months before the improvement of candida meningitis.

Table 1: Clinical features of three patients with candida meningitis at the University of Pittsburgh Medical Center.

Patient no	Patient's age(y)/sex	Underlying disease	Neurosurgical procedure	External drain (duration)	Onset of candida meningitis (no. of days post operation)	Cause of antecedent bacterial meningitis	Antibiotics previously used	Prior steroid use
1	68/F	Cavernous sinus tumor	Tumor resection	Lumbar drain (5d)	31	<i>Acinetobacter baumannii</i>	Vancomycin, Ceftazidime, Ciprofloxacin, Gentamicin	Yes
2	45/F	Meningioma	Tumor resection	External ventricular device(9d)	14	<i>Staphylococcus aureus</i>	Vancomycin, Ceftriaxone, Tobramycin, metronidazole	Yes
3	41/F	Idiopathic hydrocephalus	External ventricular device placement	External ventricular device(13d)	13	<i>Propionibacterium acnes</i>	Vancomycin, Ceftriaxone, Ciprofloxaci, penicillin	No

Likewise, two patients had accompanying bacterial and candida meningitis. The microorganisms included were *Klebsiella pneumoniae* (2 patients), *A. baumannii* (2 patients), *Serratia marcescens* (1 tolerant), *S. epidermidis* (2 patients), *S. aureus* (1 persistent), *Haemophilus injiuenzae* (1 quiet), *Enterococcus faecalis* (1 patient), and *Propionibacterium acnes* (1 understanding). Lab information. Among the 13 patients for whom such information were accessible, CSF pleocytosis was noted on the whole, with a polymorphonuclear cell power in 62% (8 of the 13). The CSF WBC checks extended from 13to 8,250/mm3. The CSF glucose level was <40 mg/dL in 12% (2 of 16), and the CSF protein level was >50 mg/dL in 69% (11 of 16). The conclusion was at first made by gram recolor for 36% of patients (five of 14). Examples from 7 of 9 patients who had extrameningeal destinations inspected and refined were sure for *Candida* species: pee (4 patients),

blood (2 patients), ventriculoperitoneal shunt catheter (1 patient), and wound and subdural liquid (1 understanding). One patient's blood and pee were both culture-positive for *Candida* species. Three extra patients had oral thrush, and two patients had skin candidiasis; societies were not performed for affirmation. Entry of entry. Neurosurgical methods as well as ventriculostomies were viewed as the entries of section in 13 patients. Candidemia happened in two patients [5, 6]. Alternate entrances were a craniotomy wound [7], an essential cerebral candida granuloma that stretched out into the meninges [3], and obscure (in one patient).

Results

The general mortality was 11%; there was no huge contrast in result for patients contaminated with *C. albicans* versus non-*C. albicans* species. Twelve patients with CNS gadgets

(shunts or ventriculostomies) (table 4). Three patients were treated with catheter evacuation alone, without antifungal treatment. One patient was relieved [5]. Candida species endured in the second patient's CSF for 9 days, yet the

patient was hence restored without antifungal treatment [8]. The third patient backslid 3 months after the fact (table 4); he was accordingly restored with amphotericin Band flucytosine [9].

Table 2: Laboratory data, therapy, and outcome for three patients with candida meningitis at University of Pittsburgh Medical Center

Patient no.	Csf values findings			Candida species isolated	Other positive cultures	Therapy and its duration		
	WBCs/mm3	RBCS/mm3	Glucose (mg/dL)			Systematic	Intrathecal	Outcome
1	81 (76%PMNs)	5	42	<i>C.tropicalis</i>	Urine	AmB (0.5MG/(KG.d) And 5FC (90mg//((KG.d)for 21 days	AmB(1mg/d)for 21 days	Persistence, then cure*
2	402 (84%PMNs)	37	149	<i>C.albicans</i>	Wound,subdural fluid collection specimen	AmB(0.5MG/(KG.d) And 5FC (90mg//((KG.d)for 41 days	AmB(1mg/d)for 41 days	Persistence, then cure*
3	26 (22%PMNs)	0	65	<i>C.parapsilosis</i>	None	Fluconazol (200mg) for 14 days	None	cure

Note: Gram stains of CSF were negative. AmB = amphotericin B; 5FC = 5-fluorocytosine (flucytosine); PMNs = polymorphonuclear cells.

* These two patients were cured after the addition of flucytosine to the treatment regimen.

Table 3: Underlying diseases and predisposing factors in the 18 cases of neurosurgical meningitis described to date.

Factors	No.(%) of patients
Neurosurgical Procedure	
Craniotomy	9(50)
Ventriculoperitoneal shunt insertion	4(22)
External ventricular device insertion	2(11)
Lumbar drain insertion	3(17)
Prior antibacterial Therapy	13(72)
Corticosteroid use	5(27)
Previous or concomitant bacterial meningitis	11(61)

The general mortality was 11%; there was no huge contrast in result for patients contaminated with *C. albicans* versus non-*C. albicans* species. Twelve patients with CNS gadgets (shunts or ventriculostomies) (table 4). Three patients were treated with catheter evacuation alone, without antifungal treatment. One patient was relieved [5]. Candida species endured in the second patient's CSF for 9 days, yet the patient was hence restored without antifungal treatment [8]. The third patient backslid 3 months after the fact (table 4); he was accordingly restored with amphotericin Band flucytosine [9].

Discussion

The general mortality was 11%; there was no huge contrast in result for patients contaminated with *C. albicans* versus non-*C. albicans* species. Twelve patients with CNS gadgets (shunts or ventriculostomies) (table 4). Three patients were treated with catheter evacuation alone, without antifungal treatment. One patient was relieved [5]. Candida species persevered in the second patient's CSF for 9 days, however the patient was along these lines relieved without antifungal treatment [8]. The third patient backslid 3 months after the fact (table 4); he was along these lines restored with amphotericin Band flucytosine [9].

Candida meningitis in neurosurgical patients is uncommon; be that as it may, the quantity of reports on this infection substance has expanded over the previous decade. At our foundation, Candida species were the fourth driving reason for meningitis in neurosurgical patients for as long as 3 years; *S. aureus*, *S. epidermidis*, and *A. baumannii* were the most well-known causes. Thirteen (72%) of the 18 patients with candida meningitis in this survey had gotten earlier foundational treatment with antibacterial specialists. The

utilization of antibacterial operators has been related with nosocomial candida circulatory system contamination [13], and it without a doubt added to the rise of candida meningitis in the cases explored. Expansive range anti-infection agents incline neurosurgical patients to disease with different anti-microbial safe microorganisms, for example, *A. baumannii* and *Stenotrophomonas maltophilia* [14-16]; Candida species ought to be added to the rundown of causes of superinfection because of anti-microbial safe life forms in post-neurosurgical meningitis. We likewise seen that bacterial meningitis went before the improvement of candida meningitis in half of patients (9 of 18); furthermore, in 67% of these patients (6 of 9), candida meningitis created amid antibacterial treatment for meningitis. The clinical indication of ailment in these patients was unmistakable in that crumbling of clinical status (for instance, repetitive fever or declining mental status) or intensifying of the pleocytosis happened in spite of proper treatment for their bacterial meningitis. The most widely recognized gateway of passage for candida meningitis was the immediate vaccination of the living being into the CNS amid medical procedure, by means of a tainted injury, or through ventriculostomy (72%; 13 of 18). The nearness of ventriculostomies has been related with meningitis, particularly when these gadgets have been set up for over 5 days [17]; the length between the ventriculostomy inclusion and the advancement of candida meningitis in this audit was 13 to 36 days. The CSF neutrophilic pleocytosis found in relationship with candida meningitis demonstrated vague from that of neurosurgery-related compound meningitis and of bacterial meningitis. Besides, the indicative yield of gram stains was just 36% (five of 14) in our arrangement. Hence, the analysis of candida meningitis should be reported by culture of the CSF. The general mortality was 11% (two of 18). The ideal antifungal treatment stays hazy; in any case, we noticed that intravenous amphotericin B conveyed a high disappointment rate in our examination (67%; two of three) (table 4). This high disappointment rate may be related with the moderately poor entrance of amphotericin B into the CSF [18]. Consequently, a few creators have pushed coordinate intraventricular organization of amphotericin B. Both achievement [19, 20] and disappointment [21] of intrathecal alongside intravenous organization of amphotericin B have been accounted for. In this survey, intrathecal amphotericin B had all the earmarks of being

moderately ineffectual in annihilating *Candida* species from the CSF; all patients aside from one (three of four) who were treated with the mix of intravenous and intrathecal amphotericin B either passed on^[6] or had constant candida disease requiring extra treatment with flucytosine for fix (patients 1 and 2). Fluconazole has been appeared at enter into the CSF^[22] and has been demonstrated viable in instances of Cryptococcal meningitis^[23]; in any case, its job in treatment of neurosurgery-related candida meningitis is hazy. In our survey, one of the two patients treated with fluconazole neglected to react. In spite of the fact that the disappointment could be ascribed to the maintenance of the ventriculoperitoneal shunt, it ought to be noticed that the CSF fluconazole level scarcely surpassed the MIC of fluconazole for this creature^[10]. We alert that the strategy for antifungal vulnerability testing was simply as of late institutionalized and, to date, the *in vitro* and *in vivo* relationship has not been entrenched. As far as we can tell, the organization of amphotericin B (0.5 mg/kg day by day) and flucytosine (somewhere around 75 mg/kg day by day) for no less than 3 weeks gave off an impression of being satisfactory treatment for neurological strategy related candida meningitis. A routine of amphotericin B and flucytosine seemed, by all accounts, to be better than one of intravenous and intrathecal amphotericin B and was related with a 100% (four of four) fix rate. The mix of these two specialists may be synergistic^[24], and flucytosine infiltrates much preferable into the CSF over does amphotericin B^[18]. In instances of shunt-or ventriculostomy-related candida meningitis, the fix rate had all the earmarks of being higher for patients whose gadget was expelled (43%; 3 of 7) than for those whose gadget stayed set up (33%; 1 of 3). Based on a ultrastructural investigation of candida shunt contamination, organization of an antifungal operator alone was viewed as probably not going to be effective in the administration of gadget related candida meningitis. A tangle of parasitic hyphae was discovered implanted in a biofilm that clings to the outside of the plastic tubing^[4]; this biofilm may obstruct the entrance of antifungal specialists. Taking everything into account, paralleling the expanded acknowledgment of *Candida* species among the blood-borne pathogens, *Candida* has been progressively perceived as a causative operator of meningitis, particularly in neurosurgical patients. *Candida* meningitis regularly has happened in patients getting wide range antibacterial treatment and the individuals who have recently had bacterial meningitis. This ailment substance ought to be suspected in neurosurgical patients with bacterial meningitis whose conditions don't react or break down in spite of fitting antibacterial treatment. The determination depends fundamentally on CSF culture, since in the cases we inspected the yield of gram recoloring was low and the CSF discoveries were indistinct from those of bacterial meningitis. Flucytosine joined with amphotericin B warrants solid thought as antifungal treatment for candida meningitis; the ideal term of antifungal treatment stays vague, however we suggest that this blend treatment be managed for no less than 3 weeks. What's more, all shunts or ventriculostomies ought to be evacuated for ideal helpful result.

References

1. Bodey GP. Hematogenous and major organ candidiasis. In G. P. Bodey (Ed.). *Candidiasis: pathogenesis, diagnosis, and treatment*. New York: Raven Press, 1993, 279-329.
2. Edwards JE Jr. *Candida species*. In: G. L. Mandell, J. E., Bennett, & R. Dolin (Eds.). *Principles and practice of infectious disease*. New York: Churchill Livingstone, 1995, 2289-2306.
3. Diamond RD. Fungal meningitis. In: H. P. Lambert (Ed.). *Infections of the central nervous system*. Philadelphia: B.C. Decker Inc, 1991, 229-245.
4. Parker JC, McCloskey JJ, Lee RS. Human cerebral candidosis-A postmortem evaluation of 19 patients. *Hum Pathol*. 1981; 12:23-28.
5. Lipton SA, Hickey WF, Morris JH, Loscalzo J. *Candida* infection in the central nervous system. *Am J Med*. 1984; 76:101-108.
6. Chmel H. *Candida albicans* meningitis following lumbar puncture. *Am J Med Sci*. 1973; 266:465-7.
7. Fisher IF, Carter MJ, Parsons J, Rissing JP. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli. *Antimicrob Agents Chemother*. 1981; 19:218-21.
8. Ikeda K, Yamashita J, Fujisawa H, Fujuta S. Cerebral granuloma and meningitis caused by *Candida albicans*: useful monitoring of mannan antigen in cerebrospinal fluid. *Neurosurgery*. 1990; 26:860-3.
9. Gower DJ, Crone K, Alexander E Jr, Kelly DL Jr. *Candida albicans* shunt infection: report of two cases. *Neurosurgery*. 1986; 19:111-3.
10. Bayer AS, Edwards JE Jr, Seidel JS, Guze LB. *Candida* meningitis: report of seven cases and review of the English literature. *Medicine (Baltimore)*. 1976; 55:477-86.
11. Gelfand MS, McGee ZA, Kaiser AB, Tally FP, Moses J. Candidal meningitis following bacterial meningitis. *South Med J*. 1990; 83:567-70.
12. Leggiadro RJ, Collins T. Post neurosurgical *Candida lusitanae* meningitis. *Pediatr Infect Dis J*. 1986; 7:368-9.
13. Sugarman B, Massanari RM. *Candida* meningitis in patients with CSF shunts. *Arch NeuroI*. 1980; 37:180-1.
14. Rodgers BM, Vries JK, Talbert JL. Laparoscopy in the diagnosis and treatment of malfunctioning ventriculoperitoneal shunts in children. *J Pediatr Surg*. 1978; 13:247-53.
15. Epelbaum S, Laurent C, Morin G, Berquin P, Piussan C. Failure of fluconazole treatment in *Candida* meningitis [letter]. *J Pediatr*. 1993; 123:168-9.
16. Chadwick DW, Hartley E, Mackinnon DM. Meningitis caused by *Candida tropicalis*. *Arch Neurol*. 1980; 37:175-6.
17. Peterson PK, Chao CC, Hu S, Thielen K, Shaskan EG. Glioblastoma, transforming growth factor-beta, and *Candida* meningitis: a potential link. *Am J Med*. 1992; 92:262-4.
18. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. *Arch Intern Med*. 1989; 149:2349-53.
19. Nguyen MH, Harris SP, Muder RR, Pasculle AW. Antibiotic-resistant *Acinetobacter* meningitis in neurosurgical patients. *Neurosurgery*. 1994; 35:851-5.
20. Nguyen MH, Muder RR. Meningitis due to *Xanthomonas maltophilia*: case report and review. *Clin Infect Dis*. 1994; 19:325-6.

21. Igra-Siegmán Y, Armstrong D, Louria DB. Culture-negative meningitis: isolation of organisms in hypertonic medium. *Isr J Med Sci.* 1981; 17:383-4.
22. Mayhall CG, Archer NH, Lamb VA *et al.* Ventriculostomy-related infections: a prospective epidemiologic study. *N Engl J Med.* 1984; 310:553-9.
23. Cherry JD, Lloyd CA, Quilty IF, Laskowski LF. Amphotericin B therapy in children: a review of the literature and a case report. *J Pediatr.* 1969; 75:1063-9.
24. Adler S, Randall J, Plotkin SA. Candidal osteomyelitis and arthritis in a neonate. *Am J Dis Child.* 1972; 123:595-6.
25. Klein JD, Yamauchi T, Horlick SP. Neonatal candidiasis, meningitis, and arthritis: observations and a review of the literature. *J Pediatr.* 1972; 81:31-4.
26. Mohan Rao HK, Myers GJ. *Candida* meningitis in the newborn. *South Med J.* 1979; 72:1468-71.
27. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. *J Infect Dis.* 1988; 157:178-80.
28. Saag MS, Powderly WG, Cloud GA *et al.* Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated Cryptococcal meningitis. *N Engl J Med.* 1992; 326:83-9.
29. Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin Band 5-fluorocytosine against yeast-like organisms. *Proc. Soc. Exp Biol. Med.* 1971; 138:571-4.
30. Chiou C-C, Wong T-T, Lin H-H *et al.* Fungal infection of ventriculoperitoneal shunts in children. *Clin Infect Dis.* 1994; 19:1049-53.
31. Sanchez-Portocarrero J, Martin-Rabadan P, Saldana CJ, Perez-Cecilia E. *Candida* cerebrospinal fluid shunt infection. Report of two new cases and review of the literature. *Diagn Microbiol Infect Dis.* 1994; 20:3340.